Geneial
Geneial is a Houston-based health technology company that operates a privacy-preserving rare disease registry platform with bidirectional REDCap integration, AI-powered ontology mapping, and mobile patient engagement, serving patient advocacy groups, academic researchers, and pharma/CROs across 30+ countries.
- Company typePrivate
- Founded2020
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Geneial does
Geneial is a Houston, Texas-based health technology company, founded in 2020, that operates a privacy-preserving, decentralized rare disease registry platform connecting patient advocacy groups, academic researchers, and pharmaceutical companies. The company targets the rare disease research market, which encompasses more than 7,000 known conditions affecting roughly 300 million people worldwide, where fewer than 5% have FDA-approved treatments and natural history studies are increasingly required for orphan drug development. Geneial's registries already span 30+ countries and cover 10+ rare diseases, anchored by deployments with the Xia-Gibbs Society (30 countries, 240+ participants) and the HNRNP Family Foundation (an umbrella registry for 10 neurodevelopmental disorders). The company is led by CEO Dr. Adam Hansen and remains privately held with no public revenue disclosure.
The platform is built on two core products and a set of AI modules. Bridge is the registry management interface for researchers and registry managers, offering a survey builder, 21 CFR Part 11-compliant eConsent, participant enrollment tracking, cohort analysis, public statistics dashboards, and bidirectional REDCap integration that allows organizations to upgrade from REDCap without data migration. Advocate is an iOS and Android mobile application for patient communities built around four pillars: Knowledge, Community, Care, and Control, with two-way sync into Bridge. The platform is reinforced by open-source AI tools: GenOMA (an agentic ontology mapping pipeline that converts patient-reported free-text into HPO, SNOMED, and ICD-10 codes with F1 ~0.96), the Geneial Transform Agent (data transformation to GA4GH Phenopackets and LinkML), a UMLS Server for high-performance biomedical terminology access, and synTOPia for privacy-preserving synthetic data generation. Infrastructure is HIPAA, 21 CFR Part 11, SOC 2 Type I, and GDPR compliant and includes a fully homomorphic encryption API for cross-registry queries.
Geneial's commercial model is tiered SaaS subscriptions (Community free, Pro custom-priced, Enterprise custom-priced) with a community-led go-to-market anchored in patient advocacy groups, supplemented by enterprise sales to pharma, CROs, and large academic institutions. A free Contact Registry tier launched in October 2025 extends a product-led growth motion into newly forming advocacy organizations. To date, the company has operated primarily on non-dilutive NIH SBIR funding totaling approximately $2.7M, with strategic relationships including Baylor College of Medicine's Human Genome Sequencing Center, NIH (NHGRI and NHLBI), ARPA-H, RENCI, and a non-binding LOI with NASDAQ-listed Lunai Bioworks.
Geneial firmographics
Firmographics- Name
- Geneial
- Legal name
- Geneial Inc.
- Website
- https://geneial.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Geneial is a Houston-based health technology company that operates a privacy-preserving rare disease registry platform with bidirectional REDCap integration, AI-powered ontology mapping, and mobile patient engagement, serving patient advocacy groups, academic researchers, and pharma/CROs across 30+ countries.
- Ownership category
- akta.pro rank
Geneial industry classification
Industry- Product category
- Rare Disease Registry Platform
- NAICS
- Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Clinical Data Repositories (CDR) & Longitudinal Patient Records (HLACAIAH)
- akta.pro secondary industries
- Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support) (HLACAIAG), FHIR/HL7 Data Repositories & Canonical Data Models (HLACAIAI), Population Genomics & Preventive Precision Health Programs (HLAAANAL)
Keywords
Where Geneial is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Geneial business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- SaaS Platform Subscriptions (Community, Pro, Enterprise): Geneial generates revenue through tiered SaaS subscription plans. The Community tier is free for organizations starting their first registry. The Pro tier (custom pricing) includes full registry capabilities, REDCap integration, eConsent, unlimited users, and priority support. The Enterprise tier adds dedicated support, custom integrations, advanced analytics, and SLA. Annual billing is implied by custom pricing and demo-first sales motion.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free tier for patient advocacy organizations starting their first registry |
| Subscription | Annual | Custom-priced tier for organizations running active registries with advanced needs |
| Subscription | Annual | Custom enterprise tier for multi-site studies and organizations with complex needs |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Geneial product offering
Product offeringCore offering
Geneial provides a privacy-preserving, decentralized rare disease registry platform consisting of Bridge (a registry management platform for researchers with survey builder, eConsent, cohort analysis, and stats dashboards) and Advocate (a patient-facing mobile app with Knowledge, Community, Care, and Control pillars). The platform integrates bidirectionally with REDCap, enforces HIPAA, 21 CFR Part 11, SOC 2 Type I, and GDPR compliance, and is augmented by proprietary AI tools (GenOMA ontology mapping, Transform Agent, UMLS Server, synTOPia synthetic data) that standardize patient-reported data to FAIR-compliant formats such as GA4GH Phenopackets and HPO codes.
Product overview
Geneial offers a platform-plus-modules architecture for rare disease registries consisting of two core products: Bridge (registry management platform for researchers/registry managers) and Advocate (mobile app for patient communities). These are complemented by AI Tools including GenOMA (ontology mapping agent), Transform Agent (data transformation), UMLS Server (terminology access), and synTOPia (synthetic data generation). The platform supports REDCap integration with bidirectional data sync, enabling organizations to upgrade from REDCap without migration. Pricing tiers include Community (free), Pro (custom), and Enterprise (custom).
Differentiator
Problem solved
Functional benefit
Brands
- Bridge: Registry command center for building surveys, managing consent, tracking enrollment, and standardizing data. Features include registry builder, eConsent, and statistics dashboard.
- Advocate
- GenOMA
- Geneial Transform Agent
- UMLS Server
- synTOPia Data Generator
Products and services
- Bridge Registry management platform for researchers and registry managers. Provides survey builder, eConsent (21 CFR Part 11), participant enrollment tracking, cohort analysis, HPO/HGVS code mapping, variant visualization, and stats dashboards. Integrates bidirectionally with REDCap and supports FAIR-compliant data standards.
- Advocate
Quantifiable outcome
- Registry deployment reduced from months to under one week using enhanced GenomeConnect survey with conditional logic and free-text fields
- +4 more outcomes
Companies that use Geneial
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Geneial technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability8 records
Feature9 records
Geneial partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and flagship.
- Lunai Bioworks (via BioSymetrics subsidiary)coreBioSymetrics (wholly owned subsidiary of NASDAQ-listed Lunai Bioworks) signed a non-binding LOI with Geneial for a strategic collaboration focused on rare neurological disorders. The collaboration aims to convert fragmented patient-generated data into trial-ready cohorts for pharmaceutical partnerships. Data across multiple patient registries and longitudinal clinical data will be integrated to support cohort development and translational research. Specific commercial terms to be defined in future definitive agreements.
- HNRNP Family FoundationcoreHNRNP Family Foundation partnered with Geneial for an umbrella registry covering 10 HNRNP-Related Neurodevelopmental Disorders (HNRNP-RNDDs). The partnership enables collection, curation, and analysis of complex data across multiple genes, research sites, and data sources. Geneial's team also supported the foundation in writing grant applications, demonstrating deep collaborative partnership beyond software provision.
- NIH (National Institutes of Health) / NHGRIcoreGeneial received NIH funding through multiple grants: $2.3M SBIR grant (September 2022, NHGRI), Phase II SBIR grant (July 2023), and Phase I SBIR award for pharmacogenomics platform (November 2023). Total NIH funding exceeds $2.7M. NIH grants fund development of privacy-preserving, decentralized platform for genetic disease research and pharmacogenomics applications.
- ARPA-H (Advanced Research Projects Agency for Health)flagshipGeneial was awarded a one-year pilot project through NHLBI BioData Catalyst (BDC) program and RENCI to partner with ARPA-H Biomedical Data Fabric (BDF) Toolbox program. Collaboration aims to advance AI tools that automate transformation of biomedical data into analysis-ready formats, supporting GA4GH Phenopackets standards. CEO Dr. Adam Hansen noted the partnership directly addresses data standardization bottlenecks in precision medicine.
- RENCI (Renaissance Computing Institute)flagshipRENCI collaborates with Geneial on a one-year pilot project through NHLBI BioData Catalyst program, partnering with ARPA-H. RENCI develops and deploys advanced technologies to enable research discoveries. The collaboration focuses on AI-driven biomedical data standardization at scale.
- NHLBI BioData Catalyst (BDC)flagshipNational Heart, Lung, and Blood Institute's BioData Catalyst program awarded Geneial a one-year pilot project alongside RENCI and ARPA-H to advance AI tools for biomedical data standardization and interoperability.
- Xia-Gibbs SocietycoreXia-Gibbs Society deployed Geneial Bridge and Advocate for their global rare disease community. The society, led by Executive Director Greg Wilkinson, manages a registry spanning 30 countries covering families affected by Xia-Gibbs Syndrome (AHDC1 gene variants). Geneial replaced a REDCap-based system managed by Baylor College of Medicine HGSC.
- Baylor College of Medicine - Human Genome Sequencing Center (HGSC)coreGeneial partnered with BCM-HGSC led by Dr. Richard Gibbs to establish a proof-of-concept for privacy-preserving data exchange using the Xia-Gibbs Syndrome registry. Successfully demonstrated advanced encryption enabling exact-match querying while protecting patient privacy. The partnership continued through a $2.3M NIH SBIR grant where Dr. Gibbs served as a collaborator and Geneial's CEO Dr. Adam Hansen was PI. HGSC transitioned registry management to the Xia-Gibbs Society using Geneial's platform.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Geneial competitors and assessment
Company assessmentDirect peers
- RARE-X: RARE-X is a non-profit-backed rare disease patient data platform that builds federated registries for advocacy groups and offers consented data sharing to researchers and pharma. Most directly comparable to Geneial in target customer (patient advocacy groups), product (registry platform), and data-sharing model — Geneial differentiates on AI ontology mapping and bidirectional REDCap integration.
- NORD (National Organization for Rare Disorders) IAMRARE Registry: NORD's IAMRARE platform is a registry infrastructure offered to US rare disease patient advocacy organizations, directly competing for the same PAG customer segment as Geneial. Both serve advocacy groups seeking compliant, easy-to-launch registries, though IAMRARE is non-profit-backed and does not offer AI ontology mapping or REDCap-grade interoperability.
Broad incumbents
- IQVIA: IQVIA operates one of the largest patient registry and real-world data businesses (E360, registry design services) serving pharma and CROs. Comparable as a competitor for pharma/CRO budget and as a benchmark for what scaled registry-plus-analytics offerings look like, though IQVIA does not specialize in rare disease advocacy-group-led registries.
- DNAnexus: DNAnexus provides a cloud genomics and biomedical data platform used by clinical and research organizations, including NIH-funded programs (All of Us, NCI). Comparable to Geneial on genomics data infrastructure and pharma-facing clinical data products, though DNAnexus operates at much larger scale and broader scope.
- TriNetX: TriNetX operates a global health research network aggregating EHR and registry data for clinical trial feasibility and real-world evidence, serving pharma and CRO customers. Comparable to Geneial on pharma-facing clinical data products and federated query, though TriNetX focuses on EHR data and trial site networks rather than patient-reported rare disease registries.
- Velsera (formerly Seven Bridges): Velsera provides a genomics data platform supporting clinical researchers and pharma with data ingestion, harmonization, and analysis workflows. Comparable to Geneial on multi-omics data standardization and pharma/research customer base, though Velsera is positioned more upstream as a sequencing/cloud infrastructure provider.
- SOPHiA GENETICS: SOPHiA GENETICS operates a genomics data analysis platform used by hospitals and research institutions, with AI-driven variant interpretation. Comparable to Geneial on AI-powered biomedical data interpretation for clinical/research customers and on GA4GH-adjacent data standardization, though SOPHiA focuses on variant calling and clinical reporting workflows.
- Flatiron Health: Flatiron Health aggregates oncology EHR and real-world data for pharma and research customers, providing regulatory-grade evidence generation. Comparable to Geneial on regulatory-grade clinical data products for pharma (especially around natural history studies and real-world evidence), though Flatiron is focused exclusively on oncology and is much larger scale.
Emerging players
- BC Platforms: BC Platforms provides a genomics and biobank data management platform serving pharma and clinical research with federated analytics. Comparable to Geneial on genomic biobank network vision, federated query (similar in spirit to Geneial's FHE work), and pharma-facing rare disease positioning, though BC Platforms is more established in European biobanks.
- RDCA-DAP (Critical Path Institute): RDCA-DAP is a collaborative rare disease data and analytics platform aggregating standardized data across multiple registries for use in regulatory-grade analyses. Comparable to Geneial on rare-disease data aggregation for FDA submissions and on data standardization mission, though RDCA-DAP is a pre-competitive consortium rather than a commercial platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Geneial social profiles
Digital presenceGeneial compliance and trust
Trust signalCompliance4 records
Geneial financial estimates
Financial estimateRevenue estimate
Valuation estimate
Geneial leadership team
Management profileNumber of profiles
Profiles3 records
Geneial funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Geneial M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Geneial
What does Geneial do?
Geneial provides a privacy-preserving, decentralized rare disease registry platform consisting of Bridge (a registry management platform for researchers with survey builder, eConsent, cohort analysis, and stats dashboards) and Advocate (a patient-facing mobile app with Knowledge, Community, Care, and Control pillars). The platform integrates bidirectionally with REDCap, enforces HIPAA, 21 CFR Part 11, SOC 2 Type I, and GDPR compliance, and is augmented by proprietary AI tools (GenOMA ontology mapping, Transform Agent, UMLS Server, synTOPia synthetic data) that standardize patient-reported data to FAIR-compliant formats such as GA4GH Phenopackets and HPO codes.
Is Geneial a public or private company?
Geneial is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Geneial founded?
Geneial was founded in 2020. It employs 1 to 10 people.
Where is Geneial based?
Geneial is headquartered in Houston, United States, in the North America region.
How does Geneial make money?
One revenue line is on record: saaS Platform Subscriptions (Community, Pro, Enterprise).
Who are Geneial's main competitors?
Direct peers on record are RARE-X and NORD (National Organization for Rare Disorders) IAMRARE Registry. Broad incumbents are IQVIA, DNAnexus, TriNetX, Velsera (formerly Seven Bridges), SOPHiA GENETICS and Flatiron Health. Emerging players are BC Platforms and RDCA-DAP (Critical Path Institute).
Does Geneial have an API?
Yes. Geneial integrates with REDCap via its API (read/write bidirectional sync). The platform also offers a Fully Homomorphic Encryption (FHE) API for private information retrieval in pharmacogenomics applications, enabling privacy-preserving queries on genomic data without exposing individual records. Additional open-source tools available on GitHub include Geneial Transform Agent, GenOMA (Ontology Mapping Agent), UMLS Server, and synTOPia Data Generator. Developer documentation is at github.com/geneialco.
What industry is Geneial in?
Geneial's product category is Rare Disease Registry Platform. Its primary akta.pro industry code is HLACAIAH, Clinical Data Repositories (CDR) & Longitudinal Patient Records, with a secondary code of HLACAIAG, Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support). Its NAICS code is 541511 and its SIC code is 7372.